ERBB2 and neoplasm: Treatment decision-making in breast cancer previously relied on conventional prognostic factors such as lymph node involvement, tumour size and grade, and status of hormone receptors (HR) and human epidermal growth factor receptor 2 (HER2); however, gene expression signatures contributed to more personalised treatment decisions6.